Zacks Investment Research·Sep 14, 2026
4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate HikeAMGN, BHC, CDNA and CNC offer defensive healthcare plays as inflation climbs and the Fed readies for a possible rate hike.
CareDx is experiencing a dramatic revenue inflection, with 2026Q2 revenue up 52.2% year-over-year to $131.9M and gross margins holding near 71.4%, suggesting strong commercial momentum in its transplant diagnostics franchise. However, the reported operating ma...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | $0.37+59.4% vs $0.23 | $132M+15.7% vs $114M |
Q2 2026 Apr 28, 2026 | $0.34+209.1% vs $0.11 | $118M+15.4% vs $102M |
Q1 2026 Feb 24, 2026 | $0.12+503.0% vs $0.02 | $108M+5.0% vs $103M |
Q4 2025 Nov 4, 2025 | $0.03+138.9% vs -$0.08 | $100M+4.9% vs $95M |
AMGN, BHC, CDNA and CNC offer defensive healthcare plays as inflation climbs and the Fed readies for a possible rate hike.
COCO, CHEF, ASMB and CDNA stand out as four defensive picks amid volatility induced by rising oil prices and Middle East tensions.
Here is how CareDx (CDNA) and Concentra Group (CON) have performed compared to their sector so far this year.
Canada Pension Plan Investment Board purchased a new position in shares of CareDx, Inc. (NASDAQ: CDNA) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 52,800 shares of the company's stock, valued at approximately $1,505,000. Canada Pension Plan Investment Board owned 0.10%
Benchmark CDNA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for CareDx, Inc (CDNA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $56.49 | $2.92B | -141.23 | 13.79% | -5.62% | -6.27% | — | |
| $390.90 | $55.98B | -257.17 | 35.9% | -7.11% | -11.73% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $1.47 | $456.58M | -0.81 | 3.89% | -82.49% | -4961.74% | — | |
| $247.46 | $37.44B | 45.41 | -0.78% | 18.36% | 31.08% | — | |
| $2.16 | $25M | -43.90 | 71.61% | -6.64% | -0.8% | — |
CareDx, Inc (CDNA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
CareDx, Inc (CDNA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
Jul 7, 2026·SEC
Jun 15, 2026·SEC
Get notified when CDNA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CareDx, Inc (CDNA) stock FAQ — growth, dividends, profitability & financials explained
CareDx, Inc (CDNA) reported $458.1M in revenue for fiscal year 2025. This represents a 2140% increase from $20.5M in 2012.
CareDx, Inc (CDNA) grew revenue by 13.8% over the past year. This is steady growth.
Yes, CareDx, Inc (CDNA) is profitable, generating $111.0M in net income for fiscal year 2025 (-5.6% net margin).
CareDx, Inc (CDNA) has a return on equity (ROE) of -6.3%. Negative ROE indicates the company is unprofitable.
CareDx, Inc (CDNA) generated $85.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
